Physician profile
Alan E Garstka
NPI 1770552853
$2,816.25
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,634 · 2020: $116 · 2021: $27.84 · 2022: $38.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,961.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $154.15 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $128.79 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.56 | 2019 | |
| Boston Scientific Corporation | $114.40 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $111.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.83 | 2019-2020 | |
| Amgen INC. | $52.54 | 2019 | |
| Pfizer INC. | $34.89 | 2019-2020 | |
| Abiomed | $33.04 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.80 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Garstka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.